Wipfli Financial Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Wipfli Financial Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$53K	Buy	+511	New	+$48.4K	﹤0.01%	1041

Other funds holding ASND

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wipfli Financial Advisors's ASND Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Ascendis Pharma A/S (ASND) in Q3 2022: 511 shares worth $53K. The stake represents ﹤0.01% of the portfolio and ranks #1041 among its holdings.

183 funds tracked by Wall St. Rank hold ASND as of Q3 2022.

Wipfli Financial Advisors held 511 shares of Ascendis Pharma A/S worth $53K as of Q3 2022.
Ascendis Pharma A/S was a new Wipfli Financial Advisors position in Q3 2022.
Ascendis Pharma A/S made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1041 holding.
183 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.